| 101 | |
| Summary | Gut microbes (species: Prevotella copri) increase Nivolumab's response to substance. |
| Gut | |
| Nivolumab (PubChem SID: 160698453) | |
| Prevotella copri (Tax ID: 165179) | |
| 31026576 | |
| increase response to substance | |
| Gut microbiome diversity greatly affects nivolumab (anti-programmed cell death 1-1) response. Non-small-cell lung carcinoma patients receiving nivolumab were classified as responders and non-responders according to unique memory CD8+ T cell and natural killer cell which produced in response to nivolumab. This classification is further correlated with the gut microbiome. Good responder showed a great diversity of favorable gut microbiome (Alistipes putredinis, Bifidobacterium longum, and Prevotella copri), While non-responders had a high abundance of Ruminococcus_unclassified. |
Browse Drug-Microbiome Relationship
Home